Literature DB >> 15598665

Red blood cells may contribute to hypercoagulability in uraemia via enhanced surface exposure of phosphatidylserine.

Mario Bonomini1, Vittorio Sirolli, Gabriele Merciaro, Teresa Antidormi, Lorenzo Di Liberato, Uwe Brummer, Marco Papponetti, Paolo Cappelli, Patrizia Di Gregorio, Arduino Arduini.   

Abstract

BACKGROUND: The exposure of phosphatidylserine (PS) on the outer leaflet of the erythrocyte membrane may have several pathophysiological consequences, including the development of a procoagulant phenotype, a finding that seems relevant to the thrombotic risk seen in many disorders.
METHODS: Because PS externalization increases in erythrocytes from patients suffering from chronic uraemia, which is frequently associated with a prothrombotic state, the possible relationship between erythrocyte PS exposure, erythrocyte procoagulant activity and plasma levels of several haemostatic markers was studied in a group of haemodialysed patients.
RESULTS: Uraemic erythrocytes displayed increased procoagulant activity, which proved to be correlated directly with erythrocyte PS exposure. Pre-incubation of uraemic erythrocytes with annexin V, a protein with high affinity and specificity for PS, strongly inhibited in vitro thrombin generation induced by erythrocytes as compared with untreated red cells. Thrombin generation and activation of fibrinolysis were found to occur in uraemic patients, as substantiated by increased plasma levels of markers for thrombin generation (prothrombin fragment F1.2 and thrombin-antithrombin complex) and fibrinolysis (D-dimer and plasmin-antiplasmin complex), respectively. Significant correlations between prothrombin fragment F1.2 and D-dimer suggested that hyperfibrinolysis was secondary to thrombin generation. Correlations were also found between erythrocyte PS levels and plasma levels of haemostatic markers, including prothrombin fragment F1.2 (P = 0.007), thrombin-antithrombin complex (P = 0.00009), plasmin-antiplasmin complex (P = 0.0009) and D-dimer (P = 0.005).
CONCLUSIONS: Our study suggests that increased PS exposure may cause a pathological erythrocyte procoagulant phenotype, which may be a factor inducing a hypercoagulable state in uraemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15598665     DOI: 10.1093/ndt/gfh622

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  Poly-N-acetylglucosamine fibers amplify the effectiveness of recombinant factor VIIA on clot formation in hemophilia B canine blood.

Authors:  Thomas H Fischer; Timothy C Nichols; Christopher M Scull; Carr J Smith; Marina Demcheva
Journal:  J Trauma       Date:  2011-08

Review 2.  Platelet and red blood cell interactions and their role in rheumatoid arthritis.

Authors:  Oore-Ofe O Olumuyiwa-Akeredolu; Etheresia Pretorius
Journal:  Rheumatol Int       Date:  2015-06-10       Impact factor: 2.631

3.  Nitric oxide synthetic pathway and cGMP levels are altered in red blood cells from end-stage renal disease patients.

Authors:  Natalia Di Pietro; Annalisa Giardinelli; Vittorio Sirolli; Chiara Riganti; Pamela Di Tomo; Elena Gazzano; Sara Di Silvestre; Christina Panknin; Miriam M Cortese-Krott; Csaba Csonka; Malte Kelm; Péter Ferdinandy; Mario Bonomini; Assunta Pandolfi
Journal:  Mol Cell Biochem       Date:  2016-05-20       Impact factor: 3.396

Review 4.  The Role of RBC Oxidative Stress in Sickle Cell Disease: From the Molecular Basis to Pathologic Implications.

Authors:  Qinhong Wang; Rahima Zennadi
Journal:  Antioxidants (Basel)       Date:  2021-10-13

5.  Whole blood platelet aggregation and release reaction testing in uremic patients.

Authors:  Jay Zeck; Jason Schallheim; Susie Q Lew; Louis DePalma
Journal:  Biomed Res Int       Date:  2013-06-26       Impact factor: 3.411

Review 6.  Oxidative Stress and Thrombosis during Aging: The Roles of Oxidative Stress in RBCs in Venous Thrombosis.

Authors:  Qinhong Wang; Rahima Zennadi
Journal:  Int J Mol Sci       Date:  2020-06-15       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.